Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient.

Rosa María García-Álvarez Maruxa Zapata-Cachafeiro Irene Visos-Varela Almudena Rodríguez-Fernández Samuel Pintos-Rodríguez María Piñeiro-Lamas María Teresa Herdeiro Adolfo Figueiras Ángel Salgado-Barreiranull null

Published in: Inflammopharmacology (2024)

This large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes.

Keyphrases

coronavirus disease
sars cov
blood pressure
electronic health record
early onset
big data
adipose tissue
metabolic syndrome
skeletal muscle
glycemic control
insulin resistance
artificial intelligence
weight loss
replacement therapy